

Table S1 Characteristics of patients with RRD treated during the three waves of the COVID pandemic and in corresponding months of 2019

	1 st year of COVID (March 2020 – February 2021)			Wave 1 (Mar 2020 – May 2020)			Wave 2 (Oct 2020 – Dec 2020)			Wave 3 (Mar 2021 – Apr 2021)		
	OR / MD	95% CI	p	OR / MD	95% CI	p	OR / MD	95% CI	p	OR / MD	95% CI	p
Sex, Female	1.39	0.79 to 2.45	0.278	2.30	0.57 to 10.60	0.307	1.37	0.38 to 5.02	0.772	0.91	0.21 to 3.84	>0.999
Age, years	-2.62	-6.05 to 0.70	0.120	-3.57	-10.22 to 3.03	0.279	1.84	-4.97 to 8.18	0.626	-2.24	-10.84 to 6.27	0.591
Duration of symptoms, days	1.50	-2.00 to 3.00	0.746	5.50	-4.00 to 11.00	0.499	3.00	-3.00 to 9.00	0.105	7.00	-5.00 to 16.00	0.646
Operated eye, Left	0.82	0.47 to 1.45	0.557	0.83	0.21 to 3.27	>0.999	0.98	0.27 to 3.55	>0.999	2.55	0.59 to 12.51	0.264
Pre-operative logMAR CDVA	-0.70	-3.00 to 1.00	0.541	-0.74	-1.18 to 0.21	0.179	0.00	-0.48 to 1.00	0.534	-0.30	-1.18 to 1.00	0.569
AXL	-0.05	-0.66 to 0.57	0.876	-0.47	-1.93 to 0.99	0.516	-1.33	-2.75 to 0.08	0.064	-0.45	-1.75 to 0.86	0.484
Lens status	-	-	0.645	-	-	0.669	-	-	0.116	-	-	>0.999
Macula status, Off	0.86	0.39 to 1.91	0.831	0.65	0.09 to 5.08	0.676	2.13	0.30 to 24.78	0.445	0.37	0.05 to 2.30	0.250
Tamponade, SF6	0.71	0.40 to 1.26	0.268	1.23	0.30 to 4.92	0.763	0.34	0.08 to 1.36	0.154	0.91	0.21 to 3.85	>0.999

Notes: Comparison for 1st year of COVID and each wave was conducted vs. corresponding period of year 2019 (as per Tables 1 and 2). Pre-COVID and COVID populations compared with t-test for age and AXL, Mann-Whitney U test for duration of symptoms and logMAR of operated eye, chi-square test for sex, operated eye, tamponade and with Fisher exact test for lens status and macula.

Abbreviations: OR, odds ratio for COVID period vs. pre-COVID period with 95% confidence interval; MD, mean/median difference calculated as COVID period minus pre-COVID period with 95% confidence interval; logMAR, the logarithm of the minimum angle of resolution; CDVA, corrected distance visual acuity; AXL, axial length; SF6, sulphur hexafluoride.

Table S2 Number of referrals due to rhegmatogenous retinal detachment per month and change versus corresponding month in 2019 (%)

Month	Number of referrals	Change vs. corresponding month in 2019 (%)
Jan 2019	11	
Feb 2019	12	
Mar 2019	13	
Apr 2019	10	
May 2019	8	
Jun 2019	6	
Jul 2019	16	
Aug 2019	12	
Sep 2019	9	
Oct 2019	11	
Nov 2019	8	
Dec 2019	8	
Jan 2020	13	18,2%
Feb 2020	7	-41,7%
Mar 2020	8	-38,5%
Apr 2020	4	-60,0%
May 2020	4	-50,0%
Jun 2020	15	150,0%
Jul 2020	14	-12,5%
Aug 2020	7	-41,7%
Sep 2020	9	0,0%
Oct 2020	9	-18,2%
Nov 2020	9	12,5%
Dec 2020	4	-50,0%

Jan 2021	13	18,2%
Feb 2021	8	-33,3%
Mar 2021	6	-53,8%
Apr 2021	11	10,0%
May 2021	8	0,0%